

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington DC 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/700,349	03/16/2001	Wolfgang Rohde	07258-022001	4891
75	90 06/06/2002			
Pillsbury Winthrop			EXAMINER	
Ninth Floor East Tower 1100 New York Avenue NW			COLLINS, C	YNTHIA E
Washington, DO	20005-3918		ART UNIT	PAPER NUMBER
			1638	
			DATE MAILED: 06/06/2002	م

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STES DEPARTMENT OF COMMERCE
Patent and Trad mark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/700349	03/16/2001	ROHDE, WOLFGANG	07258-022001

EXAMINER				
Cynthia Collins				
ART UNIT	PAPER NUMBER			
1638	6			

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- 1. Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. Mailed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:

U. S. Patent and Trademark Office 2011 South Clark Place Customer Window, Box Sequence Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at: 2011 South Clark Place Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cynthia Collins whose telephone number is (703) 605-1210. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Amy Nelson whose telephone number is (703) 306-3218. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Cynthia Collins June 4, 2002 PHUONG T. BUI PRIMARY EXAMINER

Application No.: 09/700349

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not
comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the
following reason(s):

, ,
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
oplicant Must Provide:
An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
r questions regarding compliance to these requirements, please contact:
r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY